Characterization of the , and Efficacy of the Antimicrobial Peptide DPK-060 Used for Topical Treatment

Fichier pdf chargé le 17/06/2019 à 10:50:53

(version éditeur)
TitreCharacterization of the , and Efficacy of the Antimicrobial Peptide DPK-060 Used for Topical Treatment
Type de publicationArticle de revue
AuteurHåkansson, Joakim , Ringstad, Lovisa , Umerska, Anita-Monika, Johansson, Jenny , Andersson, Therese , Boge, Lukas , Rozenbaum, René T , Sharma, Prashant K , Tollbäck, Petter , Björn, Camilla , Saulnier, Patrick , Mahlapuu, Margit
EditeurFrontiers Media SA
TypeArticle scientifique dans une revue à comité de lecture
Titre de la revueFrontiers in cellular and infection microbiology
Mots-clésantimicrobial peptides, cubosomes, DPK-060, Lipid nanocapsules, skin infections
Résumé en anglais

Antimicrobial peptides, also known as host defense peptides, have recently emerged as a promising new category of therapeutic agents for the treatment of infectious diseases. This study evaluated the preclinical , and antimicrobial activity, as well as the potential to cause skin irritation, of human kininogen-derived antimicrobial peptide DPK-060 in different formulations designed for topical delivery. We found that DPK-060 formulated in acetate buffer or poloxamer gel caused a marked reduction of bacterial counts of (minimum microbicidal concentration <5 μg/ml). We also found that DPK-060 in poloxamer gel significantly suppressed microbial survival in an wound infection model using pig skin and in an mouse model of surgical site infection (≥99 or ≥94% reduction in bacterial counts was achieved with 1% DPK-060 at 4 h post-treatment, respectively). Encapsulation of DPK-060 in different types of lipid nanocapsules or cubosomes did not improve the bactericidal potential of the peptide under the applied test conditions. No reduction in cell viability was observed in response to administration of DPK-060 in any of the formulations tested. In conclusion, the present study confirms that DPK-060 has the potential to be an effective and safe drug candidate for the topical treatment of microbial infections; however, adsorption of the peptide to nanocarriers failed to show any additional benefits.

URL de la notice
Lien vers le document

Titre abrégéFront Cell Infect Microbiol
Identifiant (ID) PubMed31192163